Akeso Invests Significantly in Lung Cancer Drug Manufacturing
0h ago|3 min readQuick Read
Fazen Markets Editorial Desk
Collective editorial team · methodology
biotechoncology
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Chinese biopharmaceutical firm Akeso is making a substantial capital investment to expand the manufacturing capacity for its lung cancer drug, cadonilimab. Chief Financial Officer Bing Wang disclosed the investment plans in an exclusive interview with Bloomberg on June 1, 2026. The strategic move is a direct response to positive Phase III clinical trial results for the drug presented at the American Society of Clinical Oncology annual meeting.
The American Society of Clinical Oncology meeting, held from May 30 to June 3, 2026, serves as a critical catalyst for biotech valuations and commercial planning. Positive data presentations often trigger immediate strategic shifts, as seen when Merck announced a $4 billion manufacturing expansion for Keytruda following its 2018 ASCO data readout. The current macro backdrop for biotech is characterized by the XBI biotech index trading near $92, up 12% year-to-date, and sustained investor appetite for oncology assets.
Akeso's cadonilimab, a PD-1/CTLA-4 bispecific antibody, demonstrated a significant improvement in progression-free survival for first-line non-small cell lung cancer patients. This data exceeded analyst expectations, creating immediate pressure to ensure supply can meet future demand. The drug’s competitive positioning against established checkpoint inhibitors from Merck and Bristol Myers Squibb necessitated a rapid operational response to capitalize on its clinical success.
Akeso’s current manufacturing capacity for cadonilimab supports approximately 50,000 treatment courses annually. The new investment aims to more than double this output to handle over 120,000 courses per year. The company’s market capitalization increased by $1.2 billion to $8.5 billion following the ASCO data presentation on May 31.
The expansion project requires an estimated investment of $300-400 million, funded through a combination of existing cash reserves and projected revenue from the drug’s sales. Cadonilimab achieved $550 million in sales in China during the 2025 fiscal year. This compares to the global oncology drug market, which eclipsed $200 billion in annual sales in 2025 according to IQVIA data.
| Metric | Before ASCO | After ASCO |
|---|---|---|
| Market Cap | $7.3B | $8.5B |
| Capacity (annual courses) | 50,000 | 120,000 (target) |
Akeso’s stock (HKEX: 9926) surged 18% on the Hong Kong exchange following the news, outperforming the Hang Seng Biotech Index, which gained 3.2% on the same day.
The manufacturing scale-up directly benefits equipment suppliers and contract development and manufacturing organizations (CDMOs). Tickers like Sartorius AG (SRT.DE) and Lonza Group (LONN.SW) typically see increased order flow from such announcements, with revenue impacts materializing within two to three quarters. Conversely, incumbent lung cancer therapy providers like Merck (MRK) and Bristol Myers Squibb (BMY) face increased competitive pressure in the Chinese market and potentially in the US upon regulatory approval.
A primary risk to the thesis is regulatory delay. The US Food and Drug Administration has not yet accepted a Biologics License Application for cadonilimab, and the review timeline remains uncertain. Institutional investors are increasing long exposure to Akeso’s Hong Kong-listed shares, with flow data indicating net buys from long-only healthcare funds throughout the week of May 27.
The key catalyst for Akeso is the formal submission to the FDA, expected in Q4 2026. Approval from China’s National Medical Products Administration (NMPA) for the first-line lung cancer indication is anticipated by Q1 2027. Investors should monitor the company’s quarterly earnings calls for updates on capital expenditure timing and revised revenue guidance.
Technically, Akeso’s stock faces resistance near the HK$65 level, a previous high from January 2026. A sustained breakout above this level on high volume would signal strong institutional conviction in the manufacturing expansion and commercial rollout. Support resides at the HK$52 level, which aligns with the 50-day moving average.
Akeso’s drug, cadonilimab, is a PD-1/CTLA-4 bispecific antibody designed to simultaneously block two immune checkpoint pathways. It is approved in China for later-line cervical cancer and is now being developed for first-line non-small cell lung cancer. The recent Phase III data demonstrated a statistically significant improvement in progression-free survival compared to chemotherapy.
Significant manufacturing investments by a leading biotech often signal capacity constraints within the industry, which can benefit CDMOs like Catalent (CTLT) and Samsung Biologics. It also raises the competitive bar for other developers of bispecific antibodies, such as Johnson & Johnson (JNJ) and Roche (RHHBY), potentially accelerating their own development and manufacturing efforts.
The availability in the US is contingent on FDA approval. Akeso has not publicly disclosed its submission timeline for a Biologics License Application, but industry analysts project a filing could occur before the end of 2026. The FDA review process typically takes 6 to 10 months, suggesting a potential 2027 launch if the application is successful and granted priority review.
Akeso's manufacturing expansion is a decisive commercial bet on its lung cancer drug's global prospects.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.